[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611760":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":10,"centralContacts":43,"locations":49,"responsibleParty":67,"collaborators":10,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":10,"enrollmentInfo":80,"targetDuration":10,"studyType":83,"phases":10,"briefSummary":84,"conditions":85,"keywords":10,"overallStatus":52,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Beni-Suef University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"SGLT2 I Group",null,"T2DM patients given SGLT2 Is + metformin added to standard of care",[13],"Drug: SGLT2 Is+METFORMIN",{"label":15,"type":10,"description":16,"interventionNames":17},"DPP4I group","T2DM patients given DPP4Is + metformin added to standard of care",[18],"Drug: DPP4 Is+metformin",{"label":20,"type":10,"description":21,"interventionNames":22},"Control group","T2DM patients given conventional therapy only",[23],"Drug: Control group",[25,32,38],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","SGLT2 Is+METFORMIN","Patients administering SGLT2 Is+metformin added to their treatment for at least the past 12 months",[9],[31],"Group 1",{"type":26,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DPP4 Is+metformin","Patients administering DPP4 I+ metformin added to their treatment for at least the past 12 months",[15],[37],"Group 2",{"type":26,"name":20,"description":39,"armGroupLabels":40,"otherNames":41},"patients administered their standard of care without any changes for the past 6 months",[20],[42],"Group 3",[44],{"name":45,"role":46,"phone":47,"phoneExt":10,"email":48},"Asmaa Abdelfattah","CONTACT","002-01095727201","asmaa_abdelfattah86@yahoo.com",[50],{"facility":51,"status":52,"city":53,"state":10,"zip":10,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Beni Suef Hospital","RECRUITING","Banī Suwayf","Egypt","EG",{"type":57,"coordinates":58},"Point",[59,60],31.09785,29.07441,{"lat":60,"lon":59},[63],{"name":64,"role":46,"phone":65,"phoneExt":10,"email":66},"Mona Kamal, Ph.D.","00201118658309","kmona3025@gmail.com",{"type":68,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Asmaa Abdelfattah Elsayed","Lecturer of clinical pharmacy","100611760","the-effects-of-some-antihyperglycemic-drugs-on-cognitive-function-and-risk-of-depression-of-diabetic-patients-100611760",false,"NCT07244770","The Effects of Some Antihyperglycemic Drugs on Cognitive Function and Risk of Depression of Diabetic Patients","MCI","Inclusion Criteria:\n\n\\-\n\nThe study participants should meet the following inclusion criteria:\n\n1. T2DM adult subjects (\\>55 years old) will be eligible to participate.\n2. Patients should be taking SGLT2Is+metformin or DDP4Is + metformin for at least 1 year to be eligible.\n\nExclusion Criteria:\n\n1- Those with type1 diabetes or ketoacidosis, insulin therapy, end organ failure as chronic renal failure, liver, and heart failure, previous history of pancreatitis, history of Alzheimer's disease or any brain insult, and finally pregnant or lactating females will be excluded from the study.","ALL","55 Years",{"count":81,"type":82},300,"ESTIMATED","OBSERVATIONAL","The study aims to investigate the effects of DPP-4 Is+ metformin versus SGLT2 Is + metformin on the risk of cognitive decline and depression in patients with T2DM.",[76],"2026-01-28",{"date":88,"type":89},"2026-01-30","ACTUAL",{"date":91,"type":89},"2025-01-01",{"date":93,"type":82},"2026-12-30",{"name":5,"class":6},1]